Compare Summit Therapeutics Inc (SMMT) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Western Union Co — how do they compare? Summit Therapeutics Inc trades at $15.25 (market cap $12.06B), while Western Union Co trades at $7.05 (market cap $2.20B). The key difference: Summit Therapeutics Inc is far larger — about 5.5× Western Union Co's market cap, and Western Union Co pays a 13.33% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WU | |
|---|---|---|
Market Cap | $12.06B | $2.20B |
Sector | Health | Technology |
52-Week High | $26.98 | $10.28 |
52-Week Low | $12.55 | $6.36 |
Enterprise Value | $11.39B | $2.10B |
Dividend Yield | — | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Western Union (WU) trades at $6.985, down 0.64% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company maintains a dividend of $0.24 per share and shows strong profitability with a 9.79% net income margin and 43.97% ROE, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Analyst consensus is mixed with a $7.14 price target, but news highlights challenges like retail money transfer weakness and strategic shifts.
The outlook is cautious due to declining revenue, earnings volatility, and bearish sentiment, though low valuation ratios (P/E of 5.69) may appeal to value investors. Risks include competitive pressures and execution hurdles in digital transitions, requiring close monitoring of upcoming Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
